Open Access

Association of CD117 and HLA‑DR expression with shorter overall survival and/or progression‑free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation

  • Authors:
    • Huan Wang
    • Xin Zhou
    • Jian‑Wei Zhu
    • Jian‑Nan Ye
    • Hong‑Feng Guo
    • Chao Sun
  • View Affiliations

  • Published online on: August 24, 2018     https://doi.org/10.3892/ol.2018.9365
  • Pages: 5655-5666
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Certain immunophenotypes in multiple myeloma (MM), including CD56 and CD117, have been reported to be associated with overall survival (OS). However, previous reports have ignored the impact of different treatment regimens and the long‑term prognostic value of immunophenotyping in MM when treated with novel agents, including thalidomide and bortezomib, in the absence of transplantation for autologous stem cell transplantation and allo‑hematopoietic stem cell transplantation. To further understand the long‑term prognostic value of immunophenotyping in MM, when treated with bortezomib combined with thalidomide‑based regimens without transplantation, 80 patients who were newly diagnosed between January 2007 and December 2015, were analyzed retrospectively. In contrast to previous studies, no significant survival time difference was observed between CD56+/CD117+ and CD56‑/CD117‑ groups. Multivariate analysis suggested that human leukocyte antigen‑antigen D‑related (HLA‑DR)+ was independently associated with shorter OS and progression‑free survival (PFS), while CD117+ was an independent prognostic factor for decreased PFS. In addition, the myeloma prognostic index (MPI), defined by HLA‑DR+, age ≥65 years and international staging system stage III, was suitable for risk stratification of patients treated with novel agents for OS and PFS. The results of the current study suggested that HLA‑DR+ patients had a shorter OS and PFS and CD117+ patients had shorter PFS. HLA‑DR+ or CD117+ was sufficient to affect survival. Evaluating these markers may reveal valuable prognostic factors for MM in patients receiving bortezomib combined with thalidomide‑based regimens without autologous stem cell transplantation and allo‑hematopoietic stem cell transplantation). MPI may describe an accessible tool to predict the prognosis of patients with MM.
View Figures
View References

Related Articles

Journal Cover

November-2018
Volume 16 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang H, Zhou X, Zhu JW, Ye JN, Guo HF and Sun C: Association of CD117 and HLA‑DR expression with shorter overall survival and/or progression‑free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation. Oncol Lett 16: 5655-5666, 2018
APA
Wang, H., Zhou, X., Zhu, J., Ye, J., Guo, H., & Sun, C. (2018). Association of CD117 and HLA‑DR expression with shorter overall survival and/or progression‑free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation. Oncology Letters, 16, 5655-5666. https://doi.org/10.3892/ol.2018.9365
MLA
Wang, H., Zhou, X., Zhu, J., Ye, J., Guo, H., Sun, C."Association of CD117 and HLA‑DR expression with shorter overall survival and/or progression‑free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation". Oncology Letters 16.5 (2018): 5655-5666.
Chicago
Wang, H., Zhou, X., Zhu, J., Ye, J., Guo, H., Sun, C."Association of CD117 and HLA‑DR expression with shorter overall survival and/or progression‑free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation". Oncology Letters 16, no. 5 (2018): 5655-5666. https://doi.org/10.3892/ol.2018.9365